Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
Identifieur interne : 001674 ( Main/Exploration ); précédent : 001673; suivant : 001675Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
Auteurs : Le-Feng Chen [République populaire de Chine] ; Ying-Qian Mo [République populaire de Chine] ; Jun Jing [République populaire de Chine] ; Jian-Da Ma [République populaire de Chine] ; Dong-Hui Zheng [République populaire de Chine] ; Lie Dai [République populaire de Chine]Source :
- International journal of rheumatic diseases [ 1756-185X ] ; 2017.
Descripteurs français
- KwdFr :
- ADN viral (génétique), Activation virale, Administration par voie intraveineuse, Adulte, Adulte d'âge moyen, Anticorps de l'hépatite B (sang), Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (effets indésirables), Antirhumatismaux (administration et posologie), Antirhumatismaux (effets indésirables), Calendrier d'administration des médicaments, Charge virale, Facteurs de risque, Facteurs temps, Femelle, Humains, Marqueurs biologiques (sang), Mâle, Polyarthrite rhumatoïde (diagnostic), Polyarthrite rhumatoïde (immunologie), Polyarthrite rhumatoïde (traitement médicamenteux), Résultat thérapeutique, Sujet immunodéprimé, Tests de la fonction hépatique, Virus de l'hépatite B (génétique), Virus de l'hépatite B (immunologie), Virus de l'hépatite B (pathogénicité), Études prospectives.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Antirhumatismaux.
- diagnostic : Polyarthrite rhumatoïde.
- effets indésirables : Anticorps monoclonaux humanisés, Antirhumatismaux.
- génétique : ADN viral, Virus de l'hépatite B.
- immunologie : Polyarthrite rhumatoïde, Virus de l'hépatite B.
- pathogénicité : Virus de l'hépatite B.
- sang : Anticorps de l'hépatite B, Marqueurs biologiques.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- Activation virale, Administration par voie intraveineuse, Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Charge virale, Facteurs de risque, Facteurs temps, Femelle, Humains, Mâle, Résultat thérapeutique, Sujet immunodéprimé, Tests de la fonction hépatique, Études prospectives.
English descriptors
- KwdEn :
- Administration, Intravenous, Adult, Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antirheumatic Agents (administration & dosage), Antirheumatic Agents (adverse effects), Arthritis, Rheumatoid (diagnosis), Arthritis, Rheumatoid (drug therapy), Arthritis, Rheumatoid (immunology), Biomarkers (blood), DNA, Viral (genetics), Drug Administration Schedule, Female, Hepatitis B Antibodies (blood), Hepatitis B virus (genetics), Hepatitis B virus (immunology), Hepatitis B virus (pathogenicity), Humans, Immunocompromised Host, Liver Function Tests, Male, Middle Aged, Prospective Studies, Risk Factors, Time Factors, Treatment Outcome, Viral Load, Virus Activation.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- chemical , blood : Biomarkers, Hepatitis B Antibodies.
- diagnosis : Arthritis, Rheumatoid.
- drug therapy : Arthritis, Rheumatoid.
- chemical , genetics : DNA, Viral, Hepatitis B virus.
- immunology : Arthritis, Rheumatoid, Hepatitis B virus.
- pathogenicity : Hepatitis B virus.
- Administration, Intravenous, Adult, Drug Administration Schedule, Female, Humans, Immunocompromised Host, Liver Function Tests, Male, Middle Aged, Prospective Studies, Risk Factors, Time Factors, Treatment Outcome, Viral Load, Virus Activation.
Abstract
To investigate the impact of short-course tocilizumab (TCZ) on hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients.
DOI: 10.1111/1756-185X.13010
PubMed: 28160426
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C28
- to stream PubMed, to step Curation: 000C28
- to stream PubMed, to step Checkpoint: 000A62
- to stream Ncbi, to step Merge: 001479
- to stream Ncbi, to step Curation: 001479
- to stream Ncbi, to step Checkpoint: 001479
- to stream Main, to step Merge: 001673
- to stream Main, to step Curation: 001674
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.</title><author><name sortKey="Chen, Le Feng" sort="Chen, Le Feng" uniqKey="Chen L" first="Le-Feng" last="Chen">Le-Feng Chen</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Mo, Ying Qian" sort="Mo, Ying Qian" uniqKey="Mo Y" first="Ying-Qian" last="Mo">Ying-Qian Mo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Jing, Jun" sort="Jing, Jun" uniqKey="Jing J" first="Jun" last="Jing">Jun Jing</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Ma, Jian Da" sort="Ma, Jian Da" uniqKey="Ma J" first="Jian-Da" last="Ma">Jian-Da Ma</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Zheng, Dong Hui" sort="Zheng, Dong Hui" uniqKey="Zheng D" first="Dong-Hui" last="Zheng">Dong-Hui Zheng</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Dai, Lie" sort="Dai, Lie" uniqKey="Dai L" first="Lie" last="Dai">Lie Dai</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28160426</idno><idno type="pmid">28160426</idno><idno type="doi">10.1111/1756-185X.13010</idno><idno type="wicri:Area/PubMed/Corpus">000C28</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C28</idno><idno type="wicri:Area/PubMed/Curation">000C28</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C28</idno><idno type="wicri:Area/PubMed/Checkpoint">000A62</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A62</idno><idno type="wicri:Area/Ncbi/Merge">001479</idno><idno type="wicri:Area/Ncbi/Curation">001479</idno><idno type="wicri:Area/Ncbi/Checkpoint">001479</idno><idno type="wicri:Area/Main/Merge">001673</idno><idno type="wicri:Area/Main/Curation">001674</idno><idno type="wicri:Area/Main/Exploration">001674</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.</title><author><name sortKey="Chen, Le Feng" sort="Chen, Le Feng" uniqKey="Chen L" first="Le-Feng" last="Chen">Le-Feng Chen</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Mo, Ying Qian" sort="Mo, Ying Qian" uniqKey="Mo Y" first="Ying-Qian" last="Mo">Ying-Qian Mo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Jing, Jun" sort="Jing, Jun" uniqKey="Jing J" first="Jun" last="Jing">Jun Jing</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Ma, Jian Da" sort="Ma, Jian Da" uniqKey="Ma J" first="Jian-Da" last="Ma">Jian-Da Ma</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Zheng, Dong Hui" sort="Zheng, Dong Hui" uniqKey="Zheng D" first="Dong-Hui" last="Zheng">Dong-Hui Zheng</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Dai, Lie" sort="Dai, Lie" uniqKey="Dai L" first="Lie" last="Dai">Lie Dai</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author></analytic><series><title level="j">International journal of rheumatic diseases</title><idno type="eISSN">1756-185X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intravenous</term><term>Adult</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Antirheumatic Agents (adverse effects)</term><term>Arthritis, Rheumatoid (diagnosis)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Arthritis, Rheumatoid (immunology)</term><term>Biomarkers (blood)</term><term>DNA, Viral (genetics)</term><term>Drug Administration Schedule</term><term>Female</term><term>Hepatitis B Antibodies (blood)</term><term>Hepatitis B virus (genetics)</term><term>Hepatitis B virus (immunology)</term><term>Hepatitis B virus (pathogenicity)</term><term>Humans</term><term>Immunocompromised Host</term><term>Liver Function Tests</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Risk Factors</term><term>Time Factors</term><term>Treatment Outcome</term><term>Viral Load</term><term>Virus Activation</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (génétique)</term><term>Activation virale</term><term>Administration par voie intraveineuse</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps de l'hépatite B (sang)</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Antirhumatismaux (administration et posologie)</term><term>Antirhumatismaux (effets indésirables)</term><term>Calendrier d'administration des médicaments</term><term>Charge virale</term><term>Facteurs de risque</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Marqueurs biologiques (sang)</term><term>Mâle</term><term>Polyarthrite rhumatoïde (diagnostic)</term><term>Polyarthrite rhumatoïde (immunologie)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Sujet immunodéprimé</term><term>Tests de la fonction hépatique</term><term>Virus de l'hépatite B (génétique)</term><term>Virus de l'hépatite B (immunologie)</term><term>Virus de l'hépatite B (pathogénicité)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term><term>Hepatitis B Antibodies</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA, Viral</term><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ADN viral</term><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Polyarthrite rhumatoïde</term><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps de l'hépatite B</term><term>Marqueurs biologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intravenous</term><term>Adult</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Immunocompromised Host</term><term>Liver Function Tests</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Risk Factors</term><term>Time Factors</term><term>Treatment Outcome</term><term>Viral Load</term><term>Virus Activation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activation virale</term><term>Administration par voie intraveineuse</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Charge virale</term><term>Facteurs de risque</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet immunodéprimé</term><term>Tests de la fonction hépatique</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To investigate the impact of short-course tocilizumab (TCZ) on hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country><region><li>Guangdong</li></region><settlement><li>Jiangmen</li></settlement></list><tree><country name="République populaire de Chine"><region name="Guangdong"><name sortKey="Chen, Le Feng" sort="Chen, Le Feng" uniqKey="Chen L" first="Le-Feng" last="Chen">Le-Feng Chen</name></region><name sortKey="Dai, Lie" sort="Dai, Lie" uniqKey="Dai L" first="Lie" last="Dai">Lie Dai</name><name sortKey="Jing, Jun" sort="Jing, Jun" uniqKey="Jing J" first="Jun" last="Jing">Jun Jing</name><name sortKey="Ma, Jian Da" sort="Ma, Jian Da" uniqKey="Ma J" first="Jian-Da" last="Ma">Jian-Da Ma</name><name sortKey="Mo, Ying Qian" sort="Mo, Ying Qian" uniqKey="Mo Y" first="Ying-Qian" last="Mo">Ying-Qian Mo</name><name sortKey="Zheng, Dong Hui" sort="Zheng, Dong Hui" uniqKey="Zheng D" first="Dong-Hui" last="Zheng">Dong-Hui Zheng</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001674 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001674 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28160426
|texte= Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28160426" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |